Announcing OMF's First ME/CFS Clinical Trial!

Get the details
Main Menu
Search
Close this search box.
Donate
Sign Up

Autoimmunity and Autoantibodies in ME/CFS

Study AIM

Investigate potential differences in adrenergic and muscarinic receptor autoantibody levels in plasma and cerebrospinal fluid (CSF) samples between ME/CFS patients and healthy controls, examine why these autoantibodies start to show up in the disease process and how we might positively impact this process with various drug targets and immune regulatory treatments. Being able to explain these underlying mechanisms may provide the validation needed for specific ongoing treatments.

LEAD INVESTIGATORS
  • Jonas Bergquist, MD, PhD, Prof, Director ScD
  • Annie Bynke, Med Student, PhD
  • Per Julin, MD, PhD , MD
  • CG Gottfries, MD, PhD, Prof em
  • Carmen Scheibenbogen, MD, PhD, Prof
Updates and Potential
  • Completed validation study on the presence of autoantibodies in plasma in two Swedish ME/CFS cohorts, and paper published.
  • Observed a significant up-regulation of autoantibodies in up to 70% of patients. Significantly increased autoantibodies against adrenergic and muscarinic receptors have been found in the plasma of ME/CFS patients.
  • No autoantibodies could be found in CFS, which is positive news as that would make the removal of autoantibodies very difficult.
  • Preliminary studies using immunoadsorption and / or plasmapheresis to remove autoantibodies show positive effects in at least a sub-population of ME/CFS patients.

Collection of data from expanded ME cohort and COVID cohort ongoing and should be ready for evaluation in fall 2023. Analysis in Berlin planned for.


STUDY HYPOTHESIS AND DESCRIPTION

The development of autoimmune antibodies is a consistent finding across HSE, ME/CFS, Long COVID and provide a window into the neurocognitive disturbances, peripheral symptoms, POTS, pain, and other targets of these autoantibodies.

Previously, autoantibodies have been observed to have increased binding to adrenergic and muscarinic receptors in ME/CFS patients. It is hypothesized

that these autoantibodies may be part of the pathogenesis of ME/CFS and patient symptom.

OBJECTIVES

Plasma, CSF and health-related questionnaires were collected from two Swedish ME / CFS cohorts, plasma and CSF from one of the cohorts (n=24), only plasma from the second cohort (n=24) together with plasma samples (n=24) and CSF (n=6) from healthy controls.

All samples were analyzed for IgG autoantibodies directed against adrenergic and muscarinic receptors ELISA technique. The questionnaires were used as measures of disease severity.

This study has been published in Brain, Behavior and Immunity – Health

Other links you might be interested in:
Scientific Advisory Board
What Is ME/CFS?
Facebook Twitter Youtube Instagram Linkedin

OMF is a non-profit 501(c)(3) organization
(EIN# 26-4712664). All donations are tax-deductible to the extent allowed by law.

Open Medicine Foundation®
29302 Laro Drive,  Agoura Hills, CA 91301 USA
Phone: 650-242-8669
info@omf.ngo

Contact Us

PRIVACY  |  COOKIE   |   CONSENT   |  MEDICAL & OTHER DISCLAIMERS

Copyright © 2023 Open Medicine Foundation. All Rights Reserved.

Consent management

Consent Preferences

Data Subject Access Request (DSAR) Form 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.


How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 
 
Donate